Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2023 | Detecting resistance to treatments in CRC with liquid biopsies

Ardaman Shergill • 26 Jan 2023
ASCO GI 2023
Colorectal Cancer Gastrointestinal Cancer

Ardaman Shergill, MD, University of Chicago, Chicago, IL, discusses the role of circulating tumor DNA (ctDNA) and liquid biopsies in patients with colorectal cancer (CRC). In the case of RAS wild-type, resistance to anti-EFGR therapies can occur, and liquid biopsies can detect tumor cells that confer resistance genes. Patients can subsequently be rechallenged with anti-EGFR regimens, and have their response assessed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ

More from Ardaman Shergill

1:07
Updates in colorectal and rectal cancer at ASCO GI 2023
Ardaman Shergill • 26 Jan 2023
1:20
Advances in predicative biomarkers for rectal cancer
Ardaman Shergill • 26 Jan 2023
5:05
Is front-line anti-EGFR therapy essential in RAS-WT mCRC?
Ardaman Shergill • 26 Jan 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals